Novanta Inc. (NOVT) Stock: Price, Forecast & Analyst Target
Novanta Inc. (NOVT) — MoonshotScore 54/100 (Fair band), calculated Nov 18, 2026. Price $117.89 (+2.22%), as of the Nov 18, 2026 trading session; market cap $4.46B.
Educational signal · not a buy or sell recommendation · How to read this
Novanta Inc. · NOVT · NASDAQ · Technology · Hardware, Equipment & Parts
Research dated 2026-09-13: Novanta manufactures advanced photonics, precision motion, and imaging components for medical and industrial customers. The company is profitable, generates positive cash flow, and has achieved profitable scale, but future growth depends on whether new market penetration and product innovation can offset commodity-like competition in its established segments.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Novanta (NOVT)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strained balance sheet and an expensive valuation, though growth is only middling. Business Quality: Average; Financial Safety: Strained; Valuation: Rich; Growth Durability: Flat; Momentum: Quiet.
- quarterly revenue $248M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 2.30 · Piotroski F 5
Holding back: balance-sheet strain
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 53 | Fair | |
| 53 | Fair | |
| 53 | Fair | |
| 53 | Fair | |
| 54 | Fair | |
| 54 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $117.89 | |
| Change on the day | +2.22% | |
| 52-week range | $98.27–$176.38 | |
| Market capitalisation | $4.46B | — |
| Price / earnings (trailing) | 86.07 | |
| Shares traded on the day | 456.0K | |
| Beta (volatility vs the S&P 500) | 1.71 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Novanta (NOVT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Novanta (NOVT), and what does it report?
Short answer · as of
Novanta operates in segments serving vastly different markets: Advanced Surgery (medical insufflators, video systems), Precision Medicine (laser diagnostics, measurement), Precision Manufacturing (industrial lasers and laser scanning), and Robotics and Automation (motion control for robots and machinery).
Research dated 2026-09-13.
Revenue is tied to capital equipment sales cycles and recurring maintenance contracts; products are engineered, not commoditized.
Reported revenue reflects a mix of product sales and service revenue. Gross margins vary by segment: high-margin laser products contrast with lower-margin surgical equipment. Operating income shows the company has reached maturity and can fund R&D from operations without diluting shareholders, unlike pure-growth stage competitors.
What do the latest results show for Novanta (NOVT)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $248M.
Research dated 2026-09-13.
Recent quarters showed stable revenue and consistent profitability. Earnings have beaten estimates consistently, suggesting the company guides conservatively or has genuine competitive advantages in execution.
The mechanism is that capital equipment cycles are predictable and Novanta's installed base of systems generates recurring revenue through consumables and service contracts. A quarter with better results signals stronger demand from OEM customers; weaker results suggest either capital spending delays or competitive pressure on pricing.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $248M | $11M | $0.30 (diluted) |
| Q4 FY2025 | $258M | $17M | $0.45 (diluted) |
| Mar 2026 | $258M | $21M | $0.51 (diluted) |
| Jun 2026 | $266M | $13M | $0.30 (diluted) |
What are the financial strengths and risks for Novanta (NOVT)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Balance sheet is strong: the company holds substantial cash, carries modest debt, and generates positive operating cash flow each quarter. Quick ratio shows the company could fund operations for many months from liquid balances. Interest coverage is healthy.
The central risk is cyclical capital equipment demand. If industrial customers delay laser system purchases or medical device companies reduce capital expenditures, Novanta revenue falls immediately. A second risk is competition: Asian manufacturers can produce simpler laser components at lower cost, creating pressure on margins in commodity segments. Novanta's profitability depends on maintaining pricing power through specialization and brand.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 86.07 runs well above the Technology sector’s ~28.90x, leaving little room for a miss.
What should you watch next at Novanta (NOVT)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.14B · EPS 3.68 · 2 analysts.
Research dated 2026-09-13.
Track bookings and backlog trends. If future order intake remains strong, that suggests underlying market demand is solid. Monitor also for customer commentary about capital spending plans: procurement delays in earnings calls would suggest near-term revenue pressure.
Watch for management commentary on competitive dynamics and pricing. If they discuss price increases sticking in the market, that signals strong demand and differentiation; if they defend current pricing, that suggests competitive intensity. Recent M&A activity (Riverpoint acquisition) warrants monitoring to see if integration adds synergies or absorbs management attention.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Nov 3, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Novanta compare with its peers?
Short answer
Novanta's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Novanta competes with diversified industrial companies like Parker Hannifin and Roper Technologies, as well as specialized laser manufacturers like IPG Photonics and Lumentum. Novanta's advantage is application-specific expertise: its systems are sold to OEM customers who need the precision and reliability, not commodity performance. That specialization justifies premium pricing.
Novanta's market position is defensible because customers invest in Novanta solutions and integrate them into their own products; switching costs are high. However, commoditization risk persists: if manufacturing advances lower the cost of precision manufacturing, customers may eventually opt for lower-cost substitutes.
| Company | Price | Market value | Score |
|---|---|---|---|
| $156.45 Nov 18, 2026 | $4.53B | 85 5-pillar Nov 18, 2026 | |
| $49.13 Nov 18, 2026 | $8.27B | 81 5-pillar Nov 18, 2026 | |
| $43.96 Nov 18, 2026 | $5.84B | 72 5-pillar Nov 18, 2026 | |
| $225.64 Nov 18, 2026 | $3.26B | 72 5-pillar Nov 18, 2026 | |
| $228.54 Nov 18, 2026 | $5.92B | 70 5-pillar Nov 18, 2026 | |
| $37.54 Nov 18, 2026 | $5.46B | 70 5-pillar Nov 18, 2026 | |
| $157.57 Nov 18, 2026 | $8.45B | 69 5-pillar Nov 18, 2026 | |
| $145.59 Nov 18, 2026 | $6.72B | 67 5-pillar Nov 18, 2026 | |
| $98.00 Nov 18, 2026 | $4.30B | 66 5-pillar Nov 18, 2026 | |
| $62.03 Nov 18, 2026 | $2.22B | 66 5-pillar Nov 18, 2026 | |
| $197.02 Nov 18, 2026 | $3.10B | 64 5-pillar Nov 18, 2026 | |
| $27.88 Nov 18, 2026 | $4.52B | 57 5-pillar Nov 18, 2026 | |
| Novanta (NOVT) — this page | $117.89 | $4.46B | 54 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $194.00 – $194.00
- Consensus target
- $194.00
- Median target
- $194.00
- Revenue estimate
- $1.14B
- EPS estimate
- $3.68
Consensus record · Captured .
Measured against a quoted price of $117.89 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 3, 2026
- Transactions
- 14
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 12
- Other transactions
- 2
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NOVT in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.06% | $13.56M | Added +5.8% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Novanta (NOVT)?
What Investors Ask About Novanta (NOVT) — Technology
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Is Novanta's growth rate sustainable?
Growth depends on market penetration, new product adoption, and favorable capital spending cycles. Recent guidance suggests steady expansion, but the company does not guide for acceleration. Maintenance of current growth requires that R&D investments yield products customers value enough to pay premium pricing.
What is the risk of commoditization?
Simpler laser systems and motion control products face commodity pressure from lower-cost manufacturers. Novanta's premium segments (medical imaging, robotic guidance) show stronger defensibility. If industrial customers migrate away from high-spec systems to lower-cost alternatives, margins would compress materially.
How much is profitability from recurring versus product sales?
Recurring revenue (maintenance, consumables, service) provides earnings stability; product sales cycles create volatility. A shift toward higher recurring revenue would reduce earnings cyclicality. Current mix gives Novanta resilience but also exposure to capital spending downturns.
Could Novanta be acquisition target or acquirer?
Novanta's profitability and cash generation make it attractive to larger industrial conglomerates seeking specialty tech. Conversely, management has pursued M&A to consolidate fragmented markets. Strategic fit depends on whether an acquirer sees synergies in distribution or R&D; Novanta's modest scale means it could enhance, not transform, a larger buyer.
What is the NOVT stock price today?
The last price recorded for Novanta Inc. (NOVT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NOVT price target?
The analyst consensus price target for Novanta Inc. (NOVT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 28 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com